MAPT and depressive symptom measurement: Interestingly, rolipram, a PDE4 inhibitor, has been shown to improve cognitive function, as well as depression- and anxiety-like behavior in transgenic mouse models of AD, possibly by inhibiting apoptosis, amyloid pathology, tau phosphorylation and neuroinflammation [125].